Dizal (jiangsu) Pharmaceutical Co. Ltd. Class ASSE: 688192

(688192)"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Receipt of a USD 600 Million Upfront Payment from AstraZeneca for the Global Licensing of ZEGFROVY

· Issued by Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Stock code 688192 ·

Announcement on Voluntary Disclosure of Receipt of a USD 600 Million Upfront Payment from AstraZeneca for the Global Licensing of ZEGFROVY

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

View original source (Shanghai Stock Exchange)Company analysis

Earlier from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

All Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A news releases